Drug Approval | February 19, 2022
Amneal expands injectables portfolio with four new products
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
It will open new frontier for south-to-south collaboration and innovation transfer
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Key takeaways of recent quarter & conference call highlights
MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India
Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Subscribe To Our Newsletter & Stay Updated
